These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1337 related items for PubMed ID: 17173260

  • 1. Membranoproliferative glomerulonephritis in a patient with Wilson's disease.
    Ozçakar ZB, Ekim M, Ensari A, Kuloglu Z, Yüksel S, Acar B, Kirsaçlioglu C, Kansu A, Yalçinkaya F, Girgin N.
    J Nephrol; 2006; 19(6):831-3. PubMed ID: 17173260
    [Abstract] [Full Text] [Related]

  • 2. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC, Hassan Y, Aziz NA, Ghazali R, Awaisu A.
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [Abstract] [Full Text] [Related]

  • 3. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A, Curiel B, Berkowitz D, Levine A, Sack J, Lorberboym M.
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [Abstract] [Full Text] [Related]

  • 4. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
    Lowette KF, Desmet K, Witters P, Laleman W, Verslype C, Nevens F, Fevery J, Cassiman DM.
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
    [Abstract] [Full Text] [Related]

  • 5. [Nephrotic syndrome after treatment with d-penicillamine in a pediatric patient with Wilson's disease].
    Farallo M, Amoruso C, Frattini C, Ardissino G, Nebbia G.
    Pediatr Med Chir; 2012 May; 34(5):234-6. PubMed ID: 23342748
    [Abstract] [Full Text] [Related]

  • 6. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG, Jonas MM, Alexander S, Herrin J, Furuta GT.
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [Abstract] [Full Text] [Related]

  • 7. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
    Sinha S, Taly AB.
    J Neurol Sci; 2008 Jan 15; 264(1-2):129-32. PubMed ID: 17765927
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis and management of Wilson's disease: results of a single center experience.
    Medici V, Trevisan CP, D'Incà R, Barollo M, Zancan L, Fagiuoli S, Martines D, Irato P, Sturniolo GC.
    J Clin Gastroenterol; 2006 Jan 15; 40(10):936-41. PubMed ID: 17063115
    [Abstract] [Full Text] [Related]

  • 9. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
    Berger B, Mader I, Damjanovic K, Niesen WD, Stich O.
    Clin Neurol Neurosurg; 2014 Dec 15; 127():122-4. PubMed ID: 25459257
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
    Haslam RH, Sass-Kortsak A, Stout W, Berg M.
    Dev Pharmacol Ther; 1980 Dec 15; 1(5):318-24. PubMed ID: 7438976
    [Abstract] [Full Text] [Related]

  • 11. [Pathogenesis and treatment of Wilson's disease].
    Nagy J, Vincze Z, Folhoffer A, Horváth A, Csák T, Zelkó R.
    Acta Pharm Hung; 2003 Dec 15; 73(4):237-41. PubMed ID: 15279036
    [Abstract] [Full Text] [Related]

  • 12. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
    Lozano Herrero J, Muñoz Bertrán E, Ortega González I, Gómez Espín R, López Espín MI.
    Gastroenterol Hepatol; 2012 Dec 15; 35(10):704-7. PubMed ID: 22609346
    [Abstract] [Full Text] [Related]

  • 13. Wilson's disease.
    Walshe JM.
    Lancet; 2007 Mar 17; 369(9565):902. PubMed ID: 17368141
    [No Abstract] [Full Text] [Related]

  • 14. Concurrent massive breast enlargement, myasthenia gravis and dermopathy as manifestations of penicillamine toxicity in a Wilson's disease patient.
    Tan SS, Latif SA, Poh WY.
    Med J Malaysia; 2012 Jun 17; 67(3):323-5. PubMed ID: 23082426
    [Abstract] [Full Text] [Related]

  • 15. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T, Tirouche YD, Abaoub-Germain A, Theodore F.
    Encephale; 2007 Dec 17; 33(6):924-32. PubMed ID: 18789784
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
    Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, Merle U, Ferenci-Foerster D, Maieron A, Stauber R, Zoller H, Schmidt HH, Reuner U, Hefter H, Trocello JM, Houwen RH, Ferenci P, Stremmel W, EUROWILSON Consortium.
    Clin Gastroenterol Hepatol; 2013 Aug 17; 11(8):1028-35.e1-2. PubMed ID: 23542331
    [Abstract] [Full Text] [Related]

  • 17. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC, Mestriner C, Irato P, Albergoni V, Longo G, D'Incà R.
    Am J Gastroenterol; 1999 Feb 17; 94(2):334-8. PubMed ID: 10022625
    [Abstract] [Full Text] [Related]

  • 18. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
    Medici V, Di Leo V, Lamboglia F, Bowlus CL, Tseng SC, D'Incà R, Irato P, Burra P, Martines D, Sturniolo GC.
    Scand J Gastroenterol; 2007 Dec 17; 42(12):1495-500. PubMed ID: 17994470
    [Abstract] [Full Text] [Related]

  • 19. D-penicillamine-induced ANA (+) ANCA (+) vasculitis in pediatric patients with Wilson's disease.
    Lee Y, Lee ST, Cho H.
    Clin Nephrol; 2016 May 17; 85(5):296-300. PubMed ID: 26784915
    [Abstract] [Full Text] [Related]

  • 20. [Late presentation of Wilson's disease].
    Santander Vaquero C.
    Rev Esp Enferm Dig; 2002 Aug 17; 94(8):502-3. PubMed ID: 12486857
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.